September 17, 2026 – PRESSADVANTAGE –

Persistent pain can interfere with sleep, mobility, work, and ordinary routines, leaving patients searching for additional approaches when symptoms continue. StrIVeMD Wellness and Ketamine is highlighting ketamine and stellate ganglion block (SGB) treatments as options within its chronic pain care in St. Charles, IL, giving patients another avenue to discuss with a qualified medical provider.

The practice’s focus on chronic pain syndromes reflects the complexity of persistent pain, which can involve more than a single source or symptom. Ketamine and SGB treatments are used in selected clinical settings to influence pain signaling, although the evidence and appropriate use vary by condition. The goal is not to promise a particular outcome, but to evaluate whether either treatment may have a place in an individual care plan.

Clinical evidence provides some context for these therapies. A systematic review and meta-analysis of randomized controlled trials published in Pain Medicine found that intravenous ketamine provided short-term analgesic benefit for refractory chronic pain, with some studies reporting effects that persisted for up to two weeks. The authors also emphasized limitations in the available research, including small studies and the need for larger trials. Another systematic review of randomized trials in neuropathic pain found reductions in pain intensity one week and 30 days after ketamine treatment. These findings support continued clinical evaluation rather than a guarantee of durable relief.

Research on SGB is similarly condition-specific. A 2024 systematic review and meta-analysis examining SGB for complex regional pain syndrome found a reduction in pain intensity compared with control groups, while noting heterogeneity among the available trials and the need for additional research. A separate review of SGB literature described evidence for several pain conditions but also concluded that stronger studies are needed. The research, therefore, does not establish SGB as a universal treatment for chronic pain.

Safety and patient selection are important parts of both therapies. FDA-approved ketamine products are indicated for anesthesia, not specifically for chronic pain, meaning pain treatment with ketamine can involve off-label use. FDA labeling lists hypersensitivity and situations in which an increase in blood pressure would pose a serious hazard among contraindications, and warns about cardiovascular changes, emergence reactions, and respiratory depression. Professional consensus guidelines also address screening, contraindications, monitoring, and management of adverse effects during ketamine infusions.

SGB is an injection-based regional anesthesia procedure and carries procedural risks that depend on the technique, medication, and patient. Reported complications can include temporary changes associated with the sympathetic block, while more serious complications are possible with cervical injections. Appropriate screening, informed consent, sterile technique, and clinical monitoring are therefore important considerations when SGB is performed.

The practice’s emphasis also reflects a point about chronic pain care: treatment decisions require more than identifying where pain is felt. Understanding duration, triggers, functional impact, prior interventions, and relevant medical history can help clinicians determine which options warrant consideration. That process keeps treatment discussions focused on circumstances instead of assuming one therapy will work the same way for every patient.

For patients researching chronic pain treatment in St. Charles, IL, a medical evaluation can help determine whether ketamine, SGB, another treatment, or a combination of approaches is appropriate. Medical history, current medications, pain diagnosis, previous treatments, cardiovascular considerations, and other factors may influence that decision. Patients can discuss expected benefits, potential risks, alternatives, and follow-up before proceeding.

StrIVeMD Wellness and Ketamine provides wellness and ketamine-based services in St. Charles, IL, including ketamine and SGB treatments for chronic pain syndromes. The practice’s approach centers on individualized evaluation and medically supervised care. For more information about available services and treatment considerations, visit the StrIVeMD Wellness and Ketamine website.

###

For more information about StrIVeMD Wellness and Ketamine, contact the company here:

StrIVeMD Wellness and Ketamine
StrIVeMD Wellness and Ketamine
(847) 213-0990
StrIVeMDWellnessKetamine@gmail.com

Media gallery

About The Author
PressAdvantage